Dr. Janicak is Professor of Psychiatry and Medical Director, Psychiatric Clinical Research Center, Rush University Medical Center, 2150 West Harrison Street, Suite 253, Chicago, IL 60612; E-mail: [email protected]; and Dr. Dowd is Assistant Professor of Psychiatry and Behavioral Sciences, and Associate Training Director for the General Psychiatry residency program, Rush University Medical Center, Chicago, IL.

Dr. Janicak has disclosed that he is/was the recipient of grant/research support from Bristol-Meyers Squibb/Otsuka, Janssen, and Neuronetics; is/was a consultant/advisor to Bristol-Meyers Squibb/ Otsuka, Janssen, AstraZeneca, and Neuronetics; and is/was a member of the speakers bureau for Bristol-Meyers Squibb/Otsuka, Janssen, Neuronetics, and Pfizer. Dr. Dowd has disclosed that she was a consultant/advisor to Neuronetics and Pfizer; was a recipient of grant/ research support from Janssen; and was/is a recipient of grant/ research support from Neuronetics and Bristol-Myers Squibb/Otsuka.

The authors also have disclosed that the use of quetiapine, risperidone, olanzapine, ziprasidone, lithium, triiodothyronine, bupropion, buspirone, stimulants, dopamine agonists, tranylcypromine, mirtazapine, nortriptyline, and deep brain stimulation for treatment of depression as discussed in this article has not been approved by the U.S. Food and Drug Administration.

All staff in a position to control the content of this CME activity have disclosed that they have no financial relationships with, or financial interests in, any commercial companies pertaining to this educational activity.

Lippincott CME Institute, Inc., has identified and resolved all faculty and staff conflicts of interest regarding this educational activity.